Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results